STTK
Shattuck Labs Inc.
$2.03
+$0.10(+5.18%)
55
Overall
60
Value
50
Tech
--
Quality
Market Cap
$127.19M
Volume
93.71K
52W Range
$0.69 - $2.71
Target Price
$2.64
Company Overview
| Mkt Cap | $127.19M | Price | $2.03 |
| Volume | 93.71K | Change | +5.18% |
| P/E Ratio | -1.7 | Open | $1.90 |
| Revenue | $5.7M | Prev Close | $1.93 |
| Net Income | $-75.4M | 52W Range | $0.69 - $2.71 |
| Div Yield | N/A | Target | $2.64 |
| Overall | 55 | Value | 60 |
| Quality | -- | Technical | 50 |
No chart data available
About Shattuck Labs Inc.
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate is SL-325, a monoclonal antibody which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Latest News
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Lemaitre Vascular (LMAT) and Shattuck Labs (STTK)
Howard Kim•16 days ago
Shattuck Labs Reports Improved Financial Performance
TipRanks Auto-Generated Newsdesk•17 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | STTK | $2.03 | +5.2% | 93.71K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |